Recent Investment Analysts’ Ratings Changes for Humacyte (HUMA)

A number of research firms have changed their ratings and price targets for Humacyte (NASDAQ: HUMA):

• 1/5/2026 – Humacyte had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
• 12/29/2025 – Humacyte had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Humacyte had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Humacyte had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
• 12/21/2025 – Humacyte was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/15/2025 – Humacyte had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/13/2025 – Humacyte was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/8/2025 – Humacyte had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Humacyte had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Humacyte had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
• 12/1/2025 – Humacyte had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 11/25/2025 – Humacyte had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/21/2025 – Humacyte had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $6.00 price target on the stock.
• 11/20/2025 – Humacyte had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
• 11/19/2025 – Humacyte had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Humacyte had its price target lowered by analysts at Benchmark Co. from $14.00 to $11.00. They now have a “buy” rating on the stock.
• 11/10/2025 – Humacyte had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.